HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and […]
Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with […]
VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 […]